181207-55-6

Basic information

• Product Name: 4-(4-PHENOXY-PHENYL)-PIPERIDINE
• Synonyms: 4-(4-PHENOXY-PHENYL)-PIPERIDINE;4-(4-Phenoxyphenyl)piperidine HCl
• CAS NO: 181207-55-6
• Molecular Formula: C₁₇H₁₉NO
• Molecular Weight: 253.34
• Mol File: 181207-55-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 378.0±42.0 °C(Predicted)
• Appearance: /
• Density: 1.067±0.06 g/cm3(Predicted)
• PKA: 10.20±0.10(Predicted)
• CAS DataBase Reference: 4-(4-PHENOXY-PHENYL)-PIPERIDINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-PHENOXY-PHENYL)-PIPERIDINE(181207-55-6)
• EPA Substance Registry System: 4-(4-PHENOXY-PHENYL)-PIPERIDINE(181207-55-6)

Safety Data

• Hazardous Substances Data: 181207-55-6(Hazardous Substances Data)

Usage

General Description

4-(4-Phenoxy-phenyl)-piperidine is a chemical compound with a piperidine ring and a phenoxy group attached to the piperidine nitrogen. It is often used as a building block in the synthesis of various pharmaceutical compounds and research chemicals. 4-(4-PHENOXY-PHENYL)-PIPERIDINE has potential applications in drug development and medicinal chemistry due to its ability to modulate receptor activity and influence biological pathways. The phenoxy group can also enhance the compound's solubility and bioavailability, making it a valuable component in the design of new drug candidates. Additionally, 4-(4-Phenoxy-phenyl)-piperidine may possess unique pharmacological properties that can make it useful in the development of novel therapies for various medical conditions.

Upstream product

• 202604-70-4 N-benzyl-4-(4-phenoxyphenyl)-4-piperidinol 
• 171350-04-2 N-tert-Butyloxycarbonyl-4-hydroxy-4-(4-phenoxyphenyl)piperidine 
• 79099-07-3 N-tert-butyloxycarbonylpiperidin-4-one 
• 101-55-3 4-Bromodiphenyl ether 
• 171350-05-3 4-(4-phenoxyphenyl)-1,2,3,6-tetrahydropyridine 

Downstream Products

• 227305-79-5 C₂₀H₂₃NO₅S 
• 687629-53-4 1-[4-(4-phenoxyphenyl)piperidin-1-yl]-3-[(4-methoxy-2-methyl)phenylamino]-2-propanol 

Relevant articles and documents

ANTHELMINTIC AGENTS AND THEIR USE

This invention is directed to compounds and salts that are generally useful as anthelmintic agents or as intermediates in processes for making anthelmintic agents. This invention also is directed to processes for making the compounds and salts, pharmaceut

Hydroxamic acid derivatives as matrix metalloprotease (MMP) inhibitors

Compounds of formula (I):or pharmaceutically or veterinarily acceptable salts thereof, or pharmaceutically or veterinarily acceptable solvates of either entity, wherein the broken line represents an optional bond; A is C or CH; B is CH2, O or absent; R1 and R2 are each independently selected from hydrogen, C1 to C6 alkyl optionally substituted with C1 to C4 alkoxy or phenyl, and C1 to C6 alkenyl; or, together with the carbon atom to which they are attached, form a C3 to C6 cycloalkyl group which optionally incorporates a heteroatom linkage selected from O, SO, SO2 and NR6 or which is optionally benzo-fused; R3 is hydrogen, halo, R7 or OR7; R4 is hydrogen, C1 to C4 alkyl, C1 to C4 alkoxy, trifluoromethyl or halo; R6 is hydrogen or C1 to C4 alkyl; R7 is an optionally substituted monocyclic or bicyclic ring system; m is 1 or 2; and n is 0, 1 or 2; with the proviso that B is not O when A is C; are MMP inhibitors useful in the treatment of, inter alia, tissue ulceration, wound repair and skin diseases.

A novel class of Na+ and Ca2+ channel dual blockers with highly potent anti-ischemic effects

A series of novel arylpiperidines (4a-d) which have highly potent blocking effects for both neuronal Na+ and T-type Ca2+ channels with extremely low affinity for dopamine D2 receptors were synthesized. Among these compounds, 1-(2-hydroxy-3-phenoxy)propyl-4-(4-phenoxyphenyl)-piperidine hydrochloride (4c; SUN N5030) exhibited remarkable neuroprotective activity in a transient middle cerebral artery occlusion (MCAO) model.